Agili-C™ Implant Performance Evaluation

Trial details

Who runs it

Smith & Nephew, Inc.

Trial code

NCT03299959

Record updated

5 December 2025

Original description

The current study compares the efficacy and safety of the Agili-C implant to Surgical Standard of Care treatment in patients suffering from joint surface lesions of the knee. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to moderate osteoarthritis, including multiple defects.Read full original descriptionShow less

A Prospective Multicenter Open-label Randomized Controlled Trial of Agili-C™ vs. Surgical Standard of Care (SSOC) for the Treatment of Joint Surface Lesions of the Knee

The current study compares the efficacy and safety of the Agili-C implant to Surgical Standard of Care treatment in patients suffering from joint surface lesions of the knee. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to moderate osteoarthritis, including multiple defects.

Inclusion: 21 -75 years; Up to 3 treatable joint surface lesion(s), ICRS Grade III or above, on the femoral condyles and/or trochlea; Symptomatic total treatable area 1-7 cm2. Asymptomatic lesions will not be included in the calculation; Must be physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits; Signed and dated the IRB/Ethics Committee approved Informed Consent Form and HIPPA (if applicable); Non-responsive to physical therapy for at least 3-4 weeks.

Exclusion: Meniscal transplantation in the past 6 months; Chemotherapy in the past 12 months; Any previous surgical cartilage treatment (such as: microfracture, ACI, OATS, etc.) in the index knee within the last 6 months; Any previous ligamentous repair or malalignment correction in the index knee within the last 6 months; Participation in other clinical trials within 60 days prior to the study or concurrent with the study; Use of anticoagulation medication or antiaggregant medication; however up to 100 mg Acetylsalicylic acid (ASA) daily is allowed; Previous intra-articular steroid injection within the last 1 month; Inability to position the implant 2mm recessed relative to the articular surface - based on MRI/X-ray/arthroscopy; Any known history of intra-articular or osseous infection of the index knee; Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, and provided that two consecutive cultures are negative (taken within at least 2 weeks of each other); Any known history of inflammatory arthropathy or crystal-deposition arthropathy; Any known systemic cartilage and/or bone disorder, such as but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta; History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies; Known insulin dependent diabetes mellitus; History of allergic reaction or intolerance of materials containing calcium carbonate or hyaluronate; KOOS Pain Subscale score at baseline is less than 20 or more than 65 (scale: maximum pain =0, pain free =100); Bony defect depth deeper than 8mm, according to baseline MRI/X-ray/arthroscopy; Articular cartilage lesions in the tibia or the patella, ICRS grades IVa or above; Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading; Significant instability of the index knee according to IKDC Knee Examination Form 2000, Grade C (abnormal) or D (severely abnormal); Malalignment more than 8 degrees varus OR 8 degrees valgus according to standing X-ray; Lack of functional remaining meniscus, at least 5mm rim at the end of the procedure; Any known tumor of the index knee; Body Mass Index (BMI) > 35; Patient who is pregnant or intends to become pregnant during the study; Known substance or alcohol abuse; Unable to undergo either MRI or X-ray; Prisoners; Uncontained lesion - Lack of vital bone wall, at least 2mm thick, completely surrounding the lesion - based on MRI/X-ray/arthroscopy.

ClinicalTrials.gov NCT03299959